CERS vs TXG vs BLFS vs NTRA vs AGEN

For growth investors, Natera, Inc.

(NTRA) is the stronger pick with 35. 9% revenue growth year-over-year, versus 5. 2% for 10x Genomics, Inc. (TXG). Analysts rate Cerus Corporation (CERS) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Natera, Inc.

(NTRA) delivered a total return of +115. 9%, compared to -93. 9% for Agenus Inc. (AGEN). Over 10 years, the gap is even starker: NTRA returned +20. 9% versus AGEN's -94. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Natera, Inc.

(NTRA) is the lower-risk stock at 1. 26β versus Agenus Inc. 's 2. 72β — meaning AGEN is approximately 117% more volatile than NTRA relative to the S&P 500. On balance sheet safety, BioLife Solutions, Inc. (BLFS) carries a lower debt/equity ratio of 5% versus 149% for Cerus Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Natera, Inc.

(NTRA) is pulling ahead at 35. 9% versus 5. 2% for 10x Genomics, Inc. (TXG). On earnings-per-share growth, the picture is similar: Agenus Inc. grew EPS 100. 0% year-over-year, compared to 0. 7% for Natera, Inc.. Over a 3-year CAGR, NTRA leads at 41. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Agenus Inc.

(AGEN) is the more profitable company, earning 0. 1% net margin versus -12. 6% for BioLife Solutions, Inc. — meaning it keeps 0. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BLFS leads at -12. 6% versus -18. 0% for AGEN. At the gross margin level — before operating expenses — AGEN leads at 90. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Agenus Inc.

(AGEN) trades at 1. 8x forward P/E versus 156. 4x for BioLife Solutions, Inc. — 154. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AGEN: 95. 5% to $7. 33.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, BioLife Solutions, Inc.

(BLFS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+1221% 10Y return). Agenus Inc. (AGEN) carries a higher beta of 2. 72 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BLFS: +1221%, AGEN: -94. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CERS is a small-cap quality compounder stock; TXG is a small-cap quality compounder stock; BLFS is a small-cap high-growth stock; NTRA is a mid-cap high-growth stock; AGEN is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.